EAAA India Alternatives’ ₹1,200 crore IPO entered its third and final day of subscription on October 28, 2026. The issue, priced at ₹1,585 to ₹1,665 per share, was subscribed 0.37 times as of 10:15 AM.
The basis of allotment is expected to be finalised on October 29, with the shares provisionally scheduled to list on the BSE and NSE on November 2, 2026.
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
26 October 2026 |
|
Subscription Closing Date |
28 October 2026 |
|
Basis of Allotment Date |
29 October 2026 |
|
Refund Initiation Date |
30 October 2026 |
|
Credit of Shares |
30 October 2026 |
|
Listing on BSE and NSE |
2 November 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
[October 28, 2026, 10:15 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.55x |
|
Non-Institutional Investors (NIIs) |
0.71x |
|
Retail Individual Investors (RIIs) |
0.12x |
|
Total |
0.37x |
Established in 2008, EAAA India Alternatives Limited is an Indian alternative investment platform with over 17 years of experience. As of June 30, 2026, it had assets under management (AUM) of ₹95,344.88 crore, with operations focused on real assets and private credit. Its business is supported by its wholly owned subsidiary, Sekura India Management Limited.
The company caters to institutional and non-institutional investors in India and international markets, including pension funds, banks, high-net-worth individuals (HNIs) and family offices. As of June 30, 2026, it served 11,009 client relationships, with a presence in Mumbai, New Delhi, GIFT City and Singapore.
|
Particulars |
For the three month period ended June 30, 2026 (in ₹ crore) |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
|
Assets |
2,101.84 |
2,170.28 |
2,085.07 |
|
Total Income |
336.13 |
963.76 |
786.54 |
|
Profit After Tax (PAT) |
80.71 |
265.20 |
229.78 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here